indicated for the treatment of partial-onset seizures in patients of four years of age and older. izures in patients of four years of age and older. Alembic Pharmaceuticals Ltd gets final approval from the USFDA for its generic version of Lacosamide tablet, indicated for the treatment of partial-onset seizures in patients of four years of age and older. The approval by the US health regulator is for the abbreviated new drug application (ANDA) for Lacosamide tablets of strengths 50 mg, 100 mg, 150 mg, and 200 mg, the company said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product Vimpat Tablets -- 50 mg, 100 mg, 150 mg, and 200 mg-of UCB Inc, it
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!